105 related articles for article (PubMed ID: 32366558)
1. Taxotere-induced WNT16 Expression in Carcinoma-Associated Fibroblasts Might Associate with Progression and Chemoresistance of Breast Cancer.
Xiang L; Song Z; Rong G
Ann Clin Lab Sci; 2020 Mar; 50(2):205-212. PubMed ID: 32366558
[TBL] [Abstract][Full Text] [Related]
2. Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs).
Rong G; Kang H; Wang Y; Hai T; Sun H
PLoS One; 2013; 8(8):e70960. PubMed ID: 23951052
[TBL] [Abstract][Full Text] [Related]
3. MMP1 and MMP11 Expression in Peripheral Blood Mononuclear Cells upon Their Interaction with Breast Cancer Cells and Fibroblasts.
Eiro N; Cid S; Aguado N; Fraile M; de Pablo N; Fernández B; Domínguez F; González LO; Vizoso FJ
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396463
[TBL] [Abstract][Full Text] [Related]
4. Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients.
Al-Ansari MM; Al-Saif M; Arafah M; Eldali AM; Tulbah A; Al-Tweigeri T; Semlali A; Khabar KS; Aboussekhra A
Breast Cancer Res; 2020 May; 22(1):49. PubMed ID: 32414408
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
Sci Rep; 2019 Nov; 9(1):16662. PubMed ID: 31723167
[TBL] [Abstract][Full Text] [Related]
6. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F
Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033
[TBL] [Abstract][Full Text] [Related]
7. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling.
Suh J; Kim DH; Lee YH; Jang JH; Surh YJ
Mol Carcinog; 2020 Sep; 59(9):1028-1040. PubMed ID: 32557854
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy.
Yang L; Zhong X; Pu T; Qiu Y; Ye F; Bu H
World J Surg Oncol; 2018 Mar; 16(1):51. PubMed ID: 29514654
[TBL] [Abstract][Full Text] [Related]
10. Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.
Wang LC; Wang LS; Li AX; Shi ZZ; Li YQ; Huang W; Chen SM; Han F; Zhu DQ
Technol Cancer Res Treat; 2020; 19():1533033820928435. PubMed ID: 32508292
[TBL] [Abstract][Full Text] [Related]
11. STEAP1 Inhibits Breast Cancer Metastasis and Is Associated With Epithelial-Mesenchymal Transition Procession.
Xie J; Yang Y; Sun J; Jiao Z; Zhang H; Chen J
Clin Breast Cancer; 2019 Feb; 19(1):e195-e207. PubMed ID: 30253922
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy.
Broad RV; Jones SJ; Teske MC; Wastall LM; Hanby AM; Thorne JL; Hughes TA
Br J Cancer; 2021 Mar; 124(6):1110-1120. PubMed ID: 33398063
[TBL] [Abstract][Full Text] [Related]
14. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
15. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.
Cid S; Eiro N; Fernández B; Sánchez R; Andicoechea A; Fernández-Muñiz PI; González LO; Vizoso FJ
Clin Breast Cancer; 2018 Feb; 18(1):e123-e133. PubMed ID: 28927692
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Raphael J; Kiss A; Nofech-Mozes S; Trudeau M
Clin Breast Cancer; 2018 Dec; 18(6):e1381-e1387. PubMed ID: 30122349
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
[TBL] [Abstract][Full Text] [Related]
20. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer.
Pereira CBL; Leal MF; Abdelhay ESFW; Demachki S; Assumpção PP; de Souza MC; Moreira-Nunes CA; Tanaka AMDS; Smith MC; Burbano RR
Clin Breast Cancer; 2017 Jun; 17(3):188-194. PubMed ID: 28089283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]